Skip to Content

Join the 'Cutaneous T-cell Lymphoma' group to help and get support from people like you.

Cutaneous T-cell Lymphoma News

Related terms: Cancer, Cutaneous T-cell Lymphoma, Lymphoma, Cutaneous T-cell Lymphoma, CTCL

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Basal Cell Carcinoma, Melanoma, Skin Cancer, Ovarian Cancer, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Testicular Cancer, Acute Lymphocytic Leukemia

Ceptaris Receives FDA Approval for Valchlor (mechlorethamine) Gel for the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma

Posted 27 Aug 2013 by

MALVERN, PA (August 26, 2013) – Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Valchlor is the first and only FDA-approved topical formulation of mechlorethamine, commonly known as nitrogen mustard. Valchlor is a gel that is applied topically once a day and dries on the skin. "This is good news for patients and the treatment community," said Youn H. Kim, M.D., Joanne and Peter Haas Jr. Professor for Cutaneous Lymphoma Research, Professor of Dermatology, and Director, Multidisciplinary Cutaneous Lymphoma Clinic, Stanford University School of Medicine. ... Read more

Related support groups: Cutaneous T-cell Lymphoma, Mycosis Fungoides

Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade

Posted 24 Nov 2010 by

WEDNESDAY, Nov. 24 – Clinicians have made remarkable advances in treating blood cancers with bone marrow and blood stem cell transplants in recent years, significantly reducing the risk of treatment-related complications and death, a new study shows. Between the early 1990s and 2007, there was a 41 percent drop in the overall risk of death in an analysis of more than 2,500 patients treated at Fred Hutchinson Cancer Center in Seattle, a leader in the field of blood cancers and other malignancies. Researchers from the Fred Hutchinson Cancer Center, who conducted the study, also noted dramatic decreases in treatment complications such as infection and organ damage. The study was published in the Nov. 24 issue of the New England Journal of Medicine "We have made enormous strides in understanding this very complex procedure and have yielded quite spectacular results," said study senior ... Read more

Related support groups: Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Cutaneous T-cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukemia, Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Chronic Eosinophilic Leukemia, Burkitt Lymphoma, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Meningeal Leukemia, Acute Myeloblastic Leukemia

Ask a Question

Further Information

Related Condition Support Groups

Mycosis Fungoides, Non-Hodgkin's Lymphoma

Related Drug Support Groups

clobetasol, Targretin, methoxsalen, bexarotene, Istodax, Zolinza, Targretin Gel, Uvadex, Actimmune, interferon gamma-1b, vorinostat, romidepsin, 8-MOP